Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Principal Investigator

  • Elizabeth Kidd

Stanford Investigator(s)

  • Nelson Teng
  • Jonathan S. Berek, MD, MMS

CONTACT INFORMATION

Primary Contact:
Elizabeth A. Kidd
(650) 725-2174